Dozens of new studies involving Schedule I and II studies—many of which employ psychedelics—are unable to commence in California, despite having clearance from the FDA, DEA and Institutional Review Boards.The cause of the hold-up? An obscure—yet apparently mandatory—checkpoint in the path to study initiation: the Research Advisory Panel of California (RAP-C).California is simultaneously the state…
